Borel Fields, Blafarm, Aiden, I agree with you.
Post# of 148170
(Total Views: 505)
Posted On: 05/11/2020 5:30:49 PM
Re: Borel Fields #33400
Borel Fields, Blafarm, Aiden,
I agree with you. The proof that Leronlimab works in Severe cases is there. I run few numbers and we will succeed no questions asked. The primary point is survival and with 88% death rate our target is very low and achievable in light of our recent success at Montefiori.
I have not doubt whatsoever about the outcome of the trial. The problem is enrollment for it.
The indication of a "peek look" at 50 patients is correct, however, I am assuming 50 patients for the placebo cohort (a total of 150 patients). Making it lengthy at the present rate. I don't believe the 50 patients mean 17 placebo plus 34 Leronlimab. There has not been clarity regarding this from any party.
Maybe we should ask NP on Wednesday this question. However, it was my sense that Nader wasn't "pushing" to hard for this. Again, it cots money to pursue a trial and this is not something we have in excess.
In regards to the Mild-to-Moderate, we have the readings from the paper of Dr. Patterson. If these repeat we will succeed big time in the P2 and I have the hope that this will be enough for FDA to say: OK, OK, it works .. let's do this and that.
I hope I am wrong, and you are right, and we can tackle the P2b/3 Severe soon. It will be successful, of that, I don't have any doubts.
I agree with you. The proof that Leronlimab works in Severe cases is there. I run few numbers and we will succeed no questions asked. The primary point is survival and with 88% death rate our target is very low and achievable in light of our recent success at Montefiori.
I have not doubt whatsoever about the outcome of the trial. The problem is enrollment for it.
The indication of a "peek look" at 50 patients is correct, however, I am assuming 50 patients for the placebo cohort (a total of 150 patients). Making it lengthy at the present rate. I don't believe the 50 patients mean 17 placebo plus 34 Leronlimab. There has not been clarity regarding this from any party.
Maybe we should ask NP on Wednesday this question. However, it was my sense that Nader wasn't "pushing" to hard for this. Again, it cots money to pursue a trial and this is not something we have in excess.
In regards to the Mild-to-Moderate, we have the readings from the paper of Dr. Patterson. If these repeat we will succeed big time in the P2 and I have the hope that this will be enough for FDA to say: OK, OK, it works .. let's do this and that.
I hope I am wrong, and you are right, and we can tackle the P2b/3 Severe soon. It will be successful, of that, I don't have any doubts.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼